Gyre Therapeutics, Inc. GYRE Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $116.59M+10.2% | $105.76M-6.8% | $113.45M— | —— | ||
| $5.42M+39.4% | $3.88M-16.2% | $4.64M-3.3% | $4.79M— | ||
| $111.17M+9.1% | $101.87M-6.4% | $108.81M+11.6% | $97.5M— | ||
| 95.4%-1.0pp | 96.3%+0.4pp | 95.9%— | —— | ||
| $13.7M+13.9% | $12.02M-12.7% | $13.78M-17.4% | $16.69M-75.8% | ||
| $65.18M+13.3% | $57.51M-6.0% | $61.16M+12.8% | $54.24M— | ||
| $20.8M+29.1% | $16.11M+9.9% | $14.66M-15.6% | $17.37M-8.4% | ||
| $105.1M+17.3% | $89.59M-50.4% | $180.68M+94.1% | $93.09M— | ||
| $11.49M-28.9% | $16.16M+124% | -$67.23M— | —— | ||
| 9.9%-5.4pp | 15.3%+74.5pp | -59.3%— | —— | ||
| -$1.51M+9.3% | -$1.66M-9.3% | -$1.52M— | —— | ||
| $14.5M-37.5% | $23.22M+130% | -$76.97M— | —— | ||
| $4.56M-14.4% | $5.32M-37.5% | $8.52M+67.0% | $5.1M— | ||
| —— | $12.18M+113% | -$92.93M-1,028% | -$8.24M+90.6% | ||
| —— | $0.05+104% | -$1.41— | —— | ||
| $13.97M-21.1% | $17.71M+127% | -$66.16M— | —— | ||
| 12%-4.8pp | 16.7%+75.1pp | -58.3%— | —— | ||
| $11.49M-28.9% | $16.16M+124% | -$67.23M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $117.0M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $1.9M over the trailing twelve months, a 6.3% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 95.1% and operating margin is -0.1%, with a 6.3% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.07.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
